Nanotechnology - Novel therapeutics for CNS disorders

Nature Reviews Neurology

Volumn 8, Issue 6, 2012, Pages 307-318

  Srikanth, Maya ^a   Kessler, John A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLCHOLINE; ANTISENSE OLIGONUCLEOTIDE; ARGINYLALANYLASPARAGINYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CARBON NANOTUBE; CENTRAL NERVOUS SYSTEM AGENTS; CILIARY NEUROTROPHIC FACTOR; CLIOQUINOL; CURCUMIN; DOXORUBICIN; FULLERENE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IRINOTECAN; ISOLEUCYLLYSYLVALYLALANYLVALINE; LIPOSOME; MACROGOL; METHOTREXATE; MOLECULAR SCAFFOLD; NANOCARRIER; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PACLITAXEL; RIVASTIGMINE; TRANSFERRIN; TRANSFERRIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; IN VITRO STUDY; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; MOLECULARLY TARGETED THERAPY; NANOANALYSIS; NANOPHARMACEUTICS; NERVE REGENERATION; NEURAL STEM CELL TRANSPLANTATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PARKINSON DISEASE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN AGGREGATION; PROTEIN TARGETING; REVIEW; SPINAL CORD INJURY;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NANOTECHNOLOGY;

EID: 84862285940     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.76     Document Type: Review

References (126)

1. Abbott, N. J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 45, 545-552 (2004
2. Nutt, J. G. & Wooten, G. F. Clinical practice. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353, 1021-1027 (2005
3. Querfurth, H. W. & LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010
4. Tanzi, R. E. & Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555 (2005
5. Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005
6. Smith, M. A. et al. Oxidative damage in Alzheimer's. Nature 382, 120-121 (1996
7. Ehmann, W. D., Markesbery, W. R., Alauddin, M., Hossain, T. I. & Brubaker, E. H. Brain trace elements in Alzheimer's disease. Neurotoxicology 7, 195-206 (1986
8. Mesulam, M., Shaw, P., Mash, D. & Weintraub, S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. Neurol. 55, 815-828 (2004
9. Brambilla, D. et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 7, 521-540 (2011
10. Kohno, T., Kobayashi, K., Maeda, T., Sato, K. & Takashima, A. Three-dimensional structures of the amyloid β peptide (25-35) in membrane-mimicking environment. Biochemistry 35, 16094-16104 (1996
11. Pai, A. S., Rubinstein, I. & Onyuksel, H. PEGylated phospholipid nanomicelles interact with β-amyloid(1-42) and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides 27, 2858-2866 (2006
12. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005
13. Taylor, M. et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide. Nanomedicine 7, 541-550 (2011
14. Mourtas, S. et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 32, 1635-1645 (2011
15. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L. & Markesbery, W. R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52 (1998
16. Cherny, R. A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (2001
17. Ritchie, C. W. et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691 (2003
18. Cui, Z. et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 263-272 (2005
19. Nomura, Y., Ikeda, M., Yamaguchi, N., Aoyama, Y. & Akiyoshi, K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett. 553, 271-276 (2003
20. Ikeda, K., Okada, T., Sawada, S., Akiyoshi, K. & Matsuzaki, K. Inhibition of the formation of amyloid β-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett. 580, 6587-6595 (2006
21. Boridy, S., Takahashi, H., Akiyoshi, K. & Maysinger, D. The binding of pullulan modified cholesteryl nanogels to Aβ oligomers and their suppression of cytotoxicity. Biomaterials 30, 5583-5591 (2009
22. Nunomura, A. et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767 (2001
23. Krusic, P. J., Wasserman, E., Keizer, P. N., Morton, J. R. & Preston, K. F. Radical reactions of c60. Science 254, 1183-1185 (1991
24. Dugan, L. L., Gabrielsen, J. K., Yu, S. P., Lin, T. S. & Choi, D. W. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol. Dis. 3, 129-135 (1996
25. Dugan, L. L. et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl Acad. Sci. USA 94, 9434-9439 (1997
26. Podolski, I. Y. et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J. Nanosci. Nanotechnol. 7, 1479-1485 (2007
27. Trinh, N. H., Hoblyn, J., Mohanty, S. & Yaffe, K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289, 210-216 (2003
28. Yang, Z. et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine 6, 427-441 (2010
29. Smart, S. K., Cassady, A. I., Lu, G. Q. & Martin, D. J. The biocompatibility of carbon nanotubes. Carbon 44, 1034-1047 (2006
30. Kim, H. R. et al. Translocation of poly(ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8, 793-799 (2007
31. Wilson, B. et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159-168 (2008
32. Joshi, S. A., Chavhan, S. S. & Sawant, K. K. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm. 76, 189-199 (2010
33. Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055-2066 (2009
34. Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508 (2004
35. Group, P. S. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59, 1937-1943 (2002
36. Witt, J. & Marks, W. J. Jr. An update on gene therapy in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11, 362-370 (2011
37. Luo, D. & Saltzman, W. M. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33-37 (2000
38. Vinogradov, S. V., Batrakova, E. V. & Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 15, 50-60 (2004
39. Zhang, Y., Calon, F., Zhu, C., Boado, R. J. & Pardridge, W. M. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14, 1-12 (2003
40. Yurek, D. M., Flectcher, A. M., Kowalczyk, T. H., Padegimas, L. & Cooper, M. J. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant 18, 1183-1196 (2009
41. Jenner, P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (Suppl. 1), 24-34 (1998
42. Lotharius, J., Dugan, L. L. & O'Malley, K. L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19, 1284-1293 (1999
43. Lin, A. M. et al. Carboxyfullerene prevents iron-induced oxidative stress in rat brain. J. Neurochem. 72, 1634-1640 (1999
44. Matsumoto, K., Sato, C., Naka, Y., Whitby, R. & Shimizu, N. Stimulation of neuronal neurite outgrowth using functionalized carbon nanotubes. Nanotechnology 21, 115101 (2010
45. Cellot, G. et al. Carbon nanotubes might improve neuronal performance by favouring electrical shortcuts. Nat. Nanotechnol. 4, 126-133 (2009
46. Mazzatenta, A. et al. Interfacing neurons with carbon nanotubes: electrical signal transfer and synaptic stimulation in cultured brain circuits. J. Neurosci. 27, 6931-6936 (2007
47. Foldvari, M. & Bagonluri, M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine 4, 183-200 (2008
48. Jia, G. et al. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ. Sci. Technol. 39, 1378-1383 (2005
49. Manna, S. K. et al. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-?B in human keratinocytes. Nano. Lett. 5, 1676-1684 (2005
50. Yehia, H. N. et al. Single-walled carbon nanotube interactions with HeLa cells. J. Nanobiotechnology 5, 8 (2007
51. Davoren, M. et al. In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol. In Vitro 21, 438-448 (2007
52. Liu, K., Tedeschi, A., Park, K. K. & He, Z. Neuronal intrinsic mechanisms of axon regeneration. Ann. Rev. Neurosci. 34, 131-152 (2011
53. Nash, M., Pribiag, H., Fournier, A. E. & Jacobson, C. Central nervous system regeneration inhibitors and their intracellular substrates. Mol. Neurobiol. 40, 224-235 (2009
54. Hannila, S. S., Siddiq, M. M. & Filbin, M. T. Therapeutic approaches to promoting axonal regeneration in the adult mammalian spinal cord. Int. Rev. Neurobiol. 77, 57-105 (2007
55. Yang, F. et al. Fabrication of nano-structured porous PLLA scaffold intended for nerve tissue engineering. Biomaterials 25, 1891-1900 (2004
56. Yang, F., Murugan, R., Wang, S. & Ramakrishna, S. Electrospinning of nano/micro scale poly(l-lactic acid) aligned fibers and their potential in neural tissue engineering. Biomaterials 26, 2603-2610 (2005
57. Moore, D. L. & Goldberg, J. L. Four steps to optic nerve regeneration. J. Neuro-ophthalmol. 30, 347-360 (2010
58. Benowitz, L. I. & Yin, Y. Optic nerve regeneration. Arch. Ophthalmol. 128, 1059-1064 (2011
59. Zhang, S., Holmes, T., Lockshin, C. & Rich, A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl Acad. Sci. USA 90, 3334-3338 (1993
60. Holmes, T. C. et al. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc. Natl Acad. Sci. USA 97, 6728-6733 (2000
61. Ellis-Behnke, R. G. et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc. Natl Acad. Sci. USA 103, 5054-5059 (2006
62. Liang, Y. X. et al. CNS regeneration after chronic injury using a self-assembled nanomaterial and MEMRI for real-time in vivo monitoring. Nanomedicine 7, 351-359 (2011
63. Meyer-Franke, A., Kaplan, M. R., Pfrieger, F. W. & Barres, B. A. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 15, 805-819 (1995
64. Burdick, J. A., Ward, M., Liang, E., Young, M. J. & Langer, R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 27, 452-459 (2006
65. Smith, G. M. & Strunz, C. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52, 209-218 (2005
66. Liu, B., Chen, H., Johns, T. G. & Neufeld, A. H. Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J. Neurosci. 26, 7532-7540 (2006
67. Koprivica, V. et al. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 310, 106-110 (2005
68. Robinson, R. et al. Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery. ACS Nano 5, 4392-4400 (2011
69. Paralysis facts & figures. Christopher & Dana Reeve Foundation Paralysis Resource Center (2010
70. Ackery, A., Tator, C. & Krassioukov, A. A global perspective on spinal cord injury epidemiology. J. Neurotrauma 21, 1355-1370 (2004
71. Schwab, M. E. Repairing the injured spinal cord. Science 295, 1029-1031 (2002
72. Sahni, V. & Kessler, J. A. Stem cell therapies for spinal cord injury. Nat. Rev. Neurol. 6, 363-372 (2010
73. Hawryluk, G. W., Rowland, J., Kwon, B. K. & Fehlings, M. G. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg. Focus 25, E14 (2008
74. Woerly, S. et al. Neural tissue formation within porous hydrogels implanted in brain and spinal cord lesions: ultrastructural, immunohistochemical, and diffusion studies. Tissue Eng. 5, 467-488 (1999
75. Tuckwell, D. S., Weston, S. A. & Humphries, M. J. Integrins: a review of their structure and mechanisms of ligand binding. Symp. Soc. Exp. Biol. 47, 107-136 (1993
76. Woerly, S., Pinet, E., de Robertis, L., Van Diep, D. & Bousmina, M. Spinal cord repair with PHPMA hydrogel containing RGD peptides (NeuroGel). Biomaterials 22, 1095-1111 (2001
77. Coumans, J. V. et al. Axonal regeneration and functional recovery after complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins. J. Neurosci. 21, 9334-9344 (2001
78. Piantino, J., Burdick, J. A., Goldberg, D., Langer, R. & Benowitz, L. I. An injectable, biodegradable hydrogel for trophic factor delivery enhances axonal rewiring and improves performance after spinal cord injury. Exp. Neurol. 201, 359-367 (2006
79. Teng, Y. D. et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc. Natl Acad. Sci. USA 99, 3024-3029 (2002
80. Rochkind, S. et al. Development of a tissue-engineered composite implant for treating traumatic paraplegia in rats. Eur. Spine J. 15, 234-245 (2006
81. Guo, J. et al. Reknitting the injured spinal cord by self-assembling peptide nanofiber scaffold. Nanomedicine 3, 311-321 (2007
82. Silva, G. A. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg. Neurol. 63, 301-306 (2005
83. Hartgerink, J. D., Beniash, E. & Stupp, S. I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science 294, 1684-1688 (2001
84. Hartgerink, J. D., Beniash, E. & Stupp, S. I. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc. Natl Acad. Sci. USA 99, 5133-5138 (2002
85. Tashiro, K. et al. A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth. J. Biol. Chem. 264, 16174-16182 (1989
86. Jucker, M., Kleinman, H. K. & Ingram, D. K. Fetal rat septal cells adhere to and extend processes on basement membrane, laminin, and a synthetic peptide from the laminin A chain sequence. J. Neurosci. Res. 28, 507-517 (1991
87. Silva, G. A. et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303, 1352-1355 (2004
88. Tysseling-Mattiace, V. M. et al. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J. Neurosci. 28, 3814-3823 (2008
89. Tysseling, V. M. et al. Self-assembling peptide amphiphile promotes plasticity of serotonergic fibers following spinal cord injury. J. Neurosci. Res. 88, 3161-3170 (2010
90. National Cancer Institute [online], http://www.nci.nih.gov/cancertopics/ types/brain/ (2012
91. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005
92. Crowley, R. W., Pouratian, N. & Sheehan, J. P. Gamma knife surgery for glioblastoma multiforme. Neurosurg. Focus 20, E17 (2006
93. Dehdashti, A. R., Hegi, M. E., Regli, L., Pica, A. & Stupp, R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg. Focus 20, E6 (2006
94. Dixit, S., Hingorani, M., Achawal, S. & Scott, I. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br. J. Neurosurg. 25, 459-469 (2011
95. Rich, J. N. et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22, 133-142 (2004
96. Gao, K. & Jiang, X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 310, 213-219 (2006
97. Tian, X. H. et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomedicine 6, 445-452 (2011
98. Huang, G., Zhang, N., Bi, X. & Dou, M. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm. 355, 314-320 (2008
99. Lamprecht, A. & Benoit, J. P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control Release 112, 208-213 (2006
100. Garcion, E. et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5, 1710-1722 (2006
101. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005
102. Dhanikula, R. S., Argaw, A., Bouchard, J. F. & Hildgen, P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm. 5, 105-116 (2008
103. He, H. et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32, 478-487 (2010
104. Hovanessian, A. G. et al. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE 5, e15787 (2010
105. Fogal, V., Sugahara, K. N., Ruoslahti, E. & Christian, S. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis 12, 91-100 (2009
106. Guo, J. et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32, 8010-8020 (2011
107. Demeule, M. et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106, 1534-1544 (2008
108. Xin, H. et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(e- caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32, 4293-4305 (2011
109. Mamot, C. et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res. 63, 3154-3161 (2003
110. Mamot, C. et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65, 11631-11638 (2005
111. Hadjipanayis, C. G. et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70, 6303-6312 (2010
112. Lu, W., Sun, Q., Wan, J., She, Z. & Jiang, X. G. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 66, 11878-11887 (2006
113. Zhang, Y., Jeong Lee, H., Boado, R. J. & Pardridge, W. M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 4, 183-194 (2002
114. Zhang, Y., Zhu, C. & Pardridge, W. M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67-72 (2002
115. Ding, H. et al. Inhibition of brain tumor growth by intravenous poly (beta-l-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc. Natl Acad. Sci. USA 107, 18143-18148 (2010
116. Agemy, L. et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl Acad. Sci. USA 108, 17450-17455 (2011
117. US National Library of Medicine. A phase I trial of nanoliposomal CPT-11 (NL CPT-11) in patients with recurrent high-grade gliomas. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00734682?term= NCT00734682&rank=1 (2011
118. Noble, C. O. et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 66, 2801-2806 (2006
119. Kunzmann, A. et al. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim. Biophys. Acta 1810, 361-373 (2010
120. Garnett, M. C. & Kallinteri, P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. (Lond.) 56, 307-311 (2006
121. Zolnik, B. S. & Sadrieh, N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv. Drug Deliv. Rev. 61, 422-427 (2009
122. Nanotechnology Task Force Report 2007. U.S. Food and Drug Administration [online], http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ NanotechnologyTaskForceReport2007/default.htm (2007
123. Vega-Villa, K. R. et al. Clinical toxicities of nanocarrier systems. Adv. Drug Deliv. Rev. 60, 929-938 (2008
124. Marano, F., Hussain, S., Rodrigues-Lima, F., Baeza-Squiban, A. & Boland, S. Nanoparticles: molecular targets and cell signalling. Arch. Toxicol. 85, 733-741 (2011
125. Singh, N. et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 30, 3891-3914 (2009
126. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469-478 (2007)